Navigation Links
IRIDEX Reports 2012 First Quarter Results
Date:5/3/2012

erience with a variety of medical devices including systems and consumables. This is a first step in improving manufacturing efficiencies previously highlighted by the Company.
  • The Company launched a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse™ technology.  The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).
  • Conference Call IRIDEX management will conduct a conference call later today, Thursday, May 3, 2012 at 5:00 p.m. Eastern Time.  Interested parties may access the live conference call via telephone by dialing (877) 941-2332 (U.S.) or (480) 629-9773 (International) and quoting Conference ID 4533749, or by visiting the Company's website at www.iridex.com. A telephone replay will be available beginning on Thursday, May 3, 2012 through Thursday, May 10, 2012 by dialing (800) 406-7325 (U.S.) or (303) 590-3030 (International) and entering Access Code 4533749. In addition, later today an archived version of the webcast will be available on the Company's website at www.iridex.com.

    About IRIDEX IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology and otolaryngology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independe
    '/>"/>

    SOURCE IRIDEX Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. IRIDEX Introduces New ENT Laser Delivery Devices at AAO-HNSF Annual Meeting
    2. IRIDEX Introduces Modular Multi-Wavelength Laser Solution at the American Academy of Ophthalmology
    3. IRIDEX Introduces IQ 532 Dual Port Green Laser System at the American Academy of Ophthalmology
    4. Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors
    5. IRIDEX Announces Fourth Quarter and Full Year 2009 Conference Call and Release Date
    6. IRIDEX Reports Fourth Quarter and Full Year 2009 Financial Results
    7. IRIDEX Announces First Quarter 2010 Conference Call and Release Date
    8. IRIDEX Announces First Commercial Shipment of New IQ 532(TM) Laser Systems
    9. IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery
    10. IRIDEX Announces Second Quarter 2010 Conference Call and Release Date
    11. IRIDEX Announces Commercial Availability of New Adjustable & Intuitive EndoProbe® Device for Eye Surgery
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/27/2015)... MALVERN, Pa. , April 27, 2015 /PRNewswire/ ... development and commercialization of products focused on the ... executive team of William Stewart and ... mark important steps in SCILEX,s proprietary drug development ... of its products. The Company,s first product, ZTlido™ ...
    (Date:4/27/2015)... 27, 2015 Harwood Feffer LLP ( www.hfesq.com ... directors of Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company") ... breached its fiduciary duties to shareholders. On ... announcing results from its first Phase 3 registration trial ... that in the trial, Rhopressa failed to meet its ...
    (Date:4/27/2015)... 27, 2015 Bronstein, Gewirtz & Grossman, LLC ... the securities of Celladon Corporation ("Celladon" or the "Company") ... Peretz Bronstein or his investor relations coordinator ... 212-697-6484. The investigation concerns whether Celladon and ... 10(b) and 20(a) of the Securities Exchange Act of ...
    Breaking Medicine Technology:SCILEX Pharmaceuticals Announces Commercial Executive Appointments 2SCILEX Pharmaceuticals Announces Commercial Executive Appointments 3Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2
    ... March 06, 2007 /PRNewswire/ -- Up to two ... up to 600,000,hospitalized. Its primary complication, pulmonary embolism ... than breast cancer and,AIDS combined. People who suffer ... DVT, because these factors also heighten the,likelihood of ...
    ... POZEN Inc.,(NASDAQ: POZN), today announced top-line results of its ... of 2006. PA 325 is a patented formulation of ... immediate release,formulation of a proton pump inhibitor., The PA ... subjects,over the age of 50. Each subject was treated ...
    Cached Medicine Technology:DVT Awareness Survey Findings: Heart and Respiratory Patients 2POZEN Announces Positive Outcome for PA 325 Proof of Concept Study 2POZEN Announces Positive Outcome for PA 325 Proof of Concept Study 3
    (Date:4/27/2015)... The Doctors on Liens mission for over ... attorneys with the best doctors working on a lien basis. ... their history and that trend continues with the addition of ... in the Tujunga / Sunland area. Featuring ... can find comprehensive care and detailed documentation of their injuries. ...
    (Date:4/27/2015)... Sitting or standing for long periods of time can ... those whose occupation requires them to be sitting while they ... to be on their feet for most of the day, ... severe and longer lasting. These people suffer from a condition ... Northeast Houston Vein Center is offering tips on how to ...
    (Date:4/27/2015)... (PRWEB) April 27, 2015 Data Integrity ... Within Your Operations or Your Partners/Suppliers, **FDAnews Webinar**, May ... http://www.fdanews.com/DataIntegrity , Data integrity issues have become ... few years., Uncovering data integrity issues within manufacturing operations ... integrity issues come to light, remediating them can be ...
    (Date:4/27/2015)... Columbus, OH (PRWEB) April 27, 2015 ... insurance to help his clients feel secure, but also helps ... a.m. to 7 p.m., Douglas will be manning a booth ... Expo Center, Lausche Building, 717 E. 17th Ave., Columbus, Ohio. ... this worthy event that will feature hundreds of adoptable pets ...
    (Date:4/27/2015)... A' Design Award and Competition is pleased ... by Boombang Inc Design Team has been announced as ... Scientific Instruments, Medical Devices and Research Equipment Design ... Boombang Inc Design Team, the creative team behind the ... Image Lumica is a two-way communication device between patients ...
    Breaking Medicine News(10 mins):Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 3Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 2Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 3Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 4Health News:Farmers Insurance Agent Douglas Fitzpatrick Ensures Pets Find Homes 2Health News:Boombang Inc Design Team wins Platinum in A' Medical Product Design Awards 2
    ... one of the largest studies in hormone receptor positive ... , PHILADELPHIA, Dec. 11 New ... (lapatinib) plus Femara(R) (letrozole) versus letrozole alone as ... metastatic breast cancer. In the study, women diagnosed with ...
    ... BOSTON, Dec. 11 The American Federation for,Medical Research ... Tom Daschle,s appointment to the post of Health and ... top,administration official to overhaul the nation,s health care system. ... result of its work since 1940, the AFMR believes ...
    ... by Matthew L. Myers, President, Campaign for Tobacco-Free Kids: , ... , , It is good ... Future survey released today finds that smoking rates among 8th, ... recorded in this survey for all three grades. However, ...
    ... released the following statement today on President-elect Obama,s nomination of ... and Human Services and naming him the Director of a ... , "Tom Daschle,s nomination as Secretary of ... the new White House Office of Health Reform is great ...
    ... among teens is slowing, survey finds , , THURSDAY, Dec. 11 ... among teens, the abuse of painkillers such as Vicodin and ... decline in the use of drugs such as marijuana has ... National Institute on Drug Abuse says in its report, ...
    ... Midwest Flooding, Indiana Tornadoes , , ... top five disasters of 2008, based on the number of people ... Gustav, Hurricane Ike, the flooding in the Midwest, and the tornadoes ... Weather played a disastrous part in many people,s lives in ...
    Cached Medicine News:Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 3Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 4Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 5Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 6Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 7Health News:The American Federation for Medical Research Says Daschle Must Cure Clinical Research Crisis if Change Is To Take Hold in U.S. Health Care System 2Health News:The American Federation for Medical Research Says Daschle Must Cure Clinical Research Crisis if Change Is To Take Hold in U.S. Health Care System 3Health News:The American Federation for Medical Research Says Daschle Must Cure Clinical Research Crisis if Change Is To Take Hold in U.S. Health Care System 4Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 2Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 3Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 4Health News:10% of U.S. High School Seniors Use Vicodin 2Health News:10% of U.S. High School Seniors Use Vicodin 3Health News:Red Cross Announces Top Five Disaster Responses of 2008 2
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: